AU2001282475A1 - Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide - Google Patents

Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide

Info

Publication number: AU2001282475A1
Authority: AU; Australia
Prior art keywords: cpg; val; dna; peptide; hspόo
Prior art date: 2000-08-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001282475A

Other languages

English (en)

Inventor

Irun R. Cohen

Francisco J. Quintana

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yeda Research and Development Co Ltd

Original Assignee

Yeda Research and Development Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-25

Filing date

2001-08-23

Publication date

2002-03-04

2001-08-23 Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd

2002-03-04 Publication of AU2001282475A1 publication Critical patent/AU2001282475A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 51
238000011282 treatment Methods 0.000 title claims description 47
208000023275 Autoimmune disease Diseases 0.000 title claims description 23
230000002265 prevention Effects 0.000 title claims description 18
108091033319 polynucleotide Proteins 0.000 title description 2
102000040430 polynucleotide Human genes 0.000 title description 2
239000002157 polynucleotide Substances 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 68
108020004414 DNA Proteins 0.000 claims description 50
239000000427 antigen Substances 0.000 claims description 42
102000036639 antigens Human genes 0.000 claims description 40
108091007433 antigens Proteins 0.000 claims description 40
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 33
108010041986 DNA Vaccines Proteins 0.000 claims description 30
229940021995 DNA vaccine Drugs 0.000 claims description 30
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 28
229960005486 vaccine Drugs 0.000 claims description 28
102000004196 processed proteins & peptides Human genes 0.000 claims description 22
229920001184 polypeptide Polymers 0.000 claims description 18
102000053602 DNA Human genes 0.000 claims description 10
150000003212 purines Chemical class 0.000 claims description 10
150000003230 pyrimidines Chemical class 0.000 claims description 10
108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 130
241000699670 Mus sp. Species 0.000 description 88
108091034117 Oligonucleotide Proteins 0.000 description 77
206010012601 diabetes mellitus Diseases 0.000 description 75
101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 58
102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 58
210000001744 T-lymphocyte Anatomy 0.000 description 44
230000004044 response Effects 0.000 description 33
102000004127 Cytokines Human genes 0.000 description 32
108090000695 Cytokines Proteins 0.000 description 32
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 29
230000000694 effects Effects 0.000 description 27
230000000638 stimulation Effects 0.000 description 25
230000002269 spontaneous effect Effects 0.000 description 21
230000006698 induction Effects 0.000 description 20
238000002347 injection Methods 0.000 description 19
239000007924 injection Substances 0.000 description 19
239000013612 plasmid Substances 0.000 description 19
241000611421 Elia Species 0.000 description 18
238000011238 DNA vaccination Methods 0.000 description 17
102000004877 Insulin Human genes 0.000 description 15
108090001061 Insulin Proteins 0.000 description 15
229940125396 insulin Drugs 0.000 description 15
239000013598 vector Substances 0.000 description 15
241000699666 Mus <mouse, genus> Species 0.000 description 14
230000006870 function Effects 0.000 description 14
230000035755 proliferation Effects 0.000 description 14
210000004989 spleen cell Anatomy 0.000 description 14
210000004988 splenocyte Anatomy 0.000 description 14
238000000338 in vitro Methods 0.000 description 13
238000011725 BALB/c mouse Methods 0.000 description 12
108010062580 Concanavalin A Proteins 0.000 description 12
230000014509 gene expression Effects 0.000 description 12
238000002255 vaccination Methods 0.000 description 12
230000001363 autoimmune Effects 0.000 description 11
230000028993 immune response Effects 0.000 description 11
230000003053 immunization Effects 0.000 description 11
238000002649 immunization Methods 0.000 description 11
230000008569 process Effects 0.000 description 11
230000009696 proliferative response Effects 0.000 description 11
102000008214 Glutamate decarboxylase Human genes 0.000 description 10
108091022930 Glutamate decarboxylase Proteins 0.000 description 10
230000004913 activation Effects 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
230000003308 immunostimulating effect Effects 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
108020000946 Bacterial DNA Proteins 0.000 description 9
238000011161 development Methods 0.000 description 9
230000018109 developmental process Effects 0.000 description 9
239000002158 endotoxin Substances 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
230000028327 secretion Effects 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
KRNYOVHEKOBTEF-YUMQZZPRSA-N Val-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O KRNYOVHEKOBTEF-YUMQZZPRSA-N 0.000 description 8
230000005784 autoimmunity Effects 0.000 description 8
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 8
201000010099 disease Diseases 0.000 description 8
229920006008 lipopolysaccharide Polymers 0.000 description 8
230000007246 mechanism Effects 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
230000009257 reactivity Effects 0.000 description 8
108010021889 valylvaline Proteins 0.000 description 8
102000006303 Chaperonin 60 Human genes 0.000 description 7
108010058432 Chaperonin 60 Proteins 0.000 description 7
230000001904 diabetogenic effect Effects 0.000 description 7
231100000673 dose–response relationship Toxicity 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 6
108010075254 C-Peptide Proteins 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
108010074328 Interferon-gamma Proteins 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
230000036039 immunity Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
238000012360 testing method Methods 0.000 description 6
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
229940046166 oligodeoxynucleotide Drugs 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
102100037850 Interferon gamma Human genes 0.000 description 4
108090000978 Interleukin-4 Proteins 0.000 description 4
241001417534 Lutjanidae Species 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
230000006052 T cell proliferation Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000006472 autoimmune response Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 4
230000003292 diminished effect Effects 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
230000011132 hemopoiesis Effects 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 3
108010002616 Interleukin-5 Proteins 0.000 description 3
101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000024932 T cell mediated immunity Effects 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 3
101800004564 Transforming growth factor alpha Proteins 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000002340 cardiotoxin Substances 0.000 description 3
231100000677 cardiotoxin Toxicity 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
230000001066 destructive effect Effects 0.000 description 3
102000046432 human HSPD1 Human genes 0.000 description 3
230000028996 humoral immune response Effects 0.000 description 3
201000001421 hyperglycemia Diseases 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 2
108091029430 CpG site Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
201000002491 encephalomyelitis Diseases 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000025020 negative regulation of T cell proliferation Effects 0.000 description 2
230000001019 normoglycemic effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
240000006108 Allium ampeloprasum Species 0.000 description 1
235000005254 Allium ampeloprasum Nutrition 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101100112922 Candida albicans CDR3 gene Proteins 0.000 description 1
101710104159 Chaperonin GroEL Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
-1 IFNγ Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000239218 Limulus Species 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100039360 Toll-like receptor 4 Human genes 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
210000005006 adaptive immune system Anatomy 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002098 anti-diabetogenic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000006470 autoimmune attack Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
244000309466 calf Species 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
108010072542 endotoxin binding proteins Proteins 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
235000003969 glutathione Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
238000002625 monoclonal antibody therapy Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000000803 paradoxical effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
108010089193 pattern recognition receptors Proteins 0.000 description 1
102000007863 pattern recognition receptors Human genes 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
230000035921 thrombopoiesis Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Marine Sciences & Fisheries (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AU2001282475A 2000-08-25 2001-08-23 Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide Abandoned AU2001282475A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22785300P	2000-08-25	2000-08-25
US60227853		2000-08-25
PCT/IL2001/000790 WO2002016549A2 (en)	2000-08-25	2001-08-23	METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE

Publications (1)

Publication Number	Publication Date
AU2001282475A1 true AU2001282475A1 (en)	2002-03-04

Family

ID=22854736

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001282475A Abandoned AU2001282475A1 (en)	2000-08-25	2001-08-23	Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide

Country Status (7)

Country	Link
US (1)	US20040005588A1 (ja)
EP (1)	EP1335741A4 (ja)
JP (1)	JP2005503320A (ja)
AU (1)	AU2001282475A1 (ja)
CA (1)	CA2420499A1 (ja)
IL (1)	IL154557A0 (ja)
WO (1)	WO2002016549A2 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN112253120A (zh) *	2020-11-26	2021-01-22	河南理工大学	煤矿废弃资源流态化共采方法
CN114215530A (zh) *	2021-11-29	2022-03-22	中国矿业大学	一种坚硬顶板定向水压致裂沿空巷道快速掘巷方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6420346B1 (en) *	2000-02-07	2002-07-16	Rappaport Family Institute For Research In The Medical Sciences	Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
DE10041853C1 (de) *	2000-08-25	2002-02-28	Gmd Gmbh	Konfigurierbares Mikroreaktornetzwerk
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) *	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
EP2301566B1 (en)	2002-05-21	2013-07-03	Irun R. Cohen	DNA vaccines encoding heat shock proteins
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
US8263091B2 (en) *	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
EP1601682B1 (en)	2003-03-12	2008-05-07	Rappaport Family Institute For Research in the Medical Sciences	Compositions and methods for diagnosing prostate cancer
US8017113B2 (en)	2003-03-12	2011-09-13	Rappaport Family Institute For Research In The Medical Sciences	Compositions and methods for diagnosing and treating an inflammation
EP1687423A4 (en) *	2003-11-24	2007-04-18	Yeda Res & Dev	HSP60 PEPTIDE FRAGMENT-ENCODING DNA VACCINES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP1789080A4 (en) *	2004-03-08	2008-12-03	Yeda Res & Dev	CD25 DNA VACCINE FOR THE CONTROL AND PREVENTION OF T-CELL-MEDIATED ILLNESSES
US8691772B2 (en)	2005-01-04	2014-04-08	Yeda Research And Development Co. Ltd.	HSP60, HSP60 peptides and T cell vaccines for immunomodulation
ATE542540T1 (de)	2007-09-11	2012-02-15	Uinv Kobenhavns	Vorbeugung von diabetes durch verabreichung von gliadin
ITRM20080529A1 (it) *	2008-10-07	2010-04-08	Uni Degli Studi Perugia	Uso della l-chinurenina e suoi derivati per la prevenzione ed il trattamento del diabete mellito di tipo 1.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP1167378B1 (en) *	1994-07-15	2011-05-11	University of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6180103B1 (en) *	1994-12-21	2001-01-30	Yeda Research And Development Co., Ltd.	Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
CN1233417C (zh) *	1994-12-21	2005-12-28	耶达研究与发展有限公司	肽p277类似物及含有它们的诊断和治疗糖尿病的药物组合物
US6110746A (en) *	1995-06-30	2000-08-29	Yeda Research And Development Co. Ltd.	Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
IL114407A0 (en) *	1995-06-30	1995-10-31	Yeda Res & Dev	Novel peptides and pharmaceutical compositions comprising them
US5993803A (en) *	1996-08-30	1999-11-30	Yeda Research And Development Co., Ltd.	Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU755322B2 (en) *	1997-06-06	2002-12-12	Dynavax Technologies Corporation	Inhibitors of DNA immunostimulatory sequence activity
DE69837094T2 (de) *	1997-09-05	2007-08-30	The Regents Of The University Of California, Oakland	Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US6541011B2 (en) *	1998-02-11	2003-04-01	Maxygen, Inc.	Antigen library immunization
AU3558899A (en) *	1998-04-13	1999-11-01	Brigham And Women's Hospital	Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
EP1100807A1 (en) *	1998-07-27	2001-05-23	University Of Iowa Research Foundation	STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
US7030098B2 (en) *	1999-03-12	2006-04-18	The Board Of Trustees Of The Leland Stanford Junior University	DNA vaccination for treatment of autoimmune disease
CN1227030C (zh) *	1999-04-19	2005-11-16	史密丝克莱恩比彻姆生物有限公司	包含皂甙和免疫刺激寡核苷酸的佐剂组合物
AU2001227889A1 (en) *	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
JP2005510533A (ja) *	2001-11-21	2005-04-21	ザボードオブトラスティーズオブレランドスタンフォードジュニアユニバーシティ	ポリヌクレオチド療法
EP2301566B1 (en) *	2002-05-21	2013-07-03	Irun R. Cohen	DNA vaccines encoding heat shock proteins
GB0212648D0 (en) *	2002-05-31	2002-07-10	Immunoclin Lab Ltd	Treatment with cytokines
WO2004045376A2 (en) *	2002-11-15	2004-06-03	The General Hospital Corporation	Screening methods to identify treatments for autoimmune disease

2001
- 2001-08-23 JP JP2002521625A patent/JP2005503320A/ja active Pending
- 2001-08-23 EP EP01961097A patent/EP1335741A4/en not_active Withdrawn
- 2001-08-23 AU AU2001282475A patent/AU2001282475A1/en not_active Abandoned
- 2001-08-23 WO PCT/IL2001/000790 patent/WO2002016549A2/en not_active Application Discontinuation
- 2001-08-23 IL IL15455701A patent/IL154557A0/xx unknown
- 2001-08-23 CA CA002420499A patent/CA2420499A1/en not_active Abandoned
2003
- 2003-02-24 US US10/371,116 patent/US20040005588A1/en not_active Abandoned

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN112253120A (zh) *	2020-11-26	2021-01-22	河南理工大学	煤矿废弃资源流态化共采方法
CN112253120B (zh) *	2020-11-26	2023-06-09	河南理工大学	煤矿废弃资源流态化共采方法
CN114215530A (zh) *	2021-11-29	2022-03-22	中国矿业大学	一种坚硬顶板定向水压致裂沿空巷道快速掘巷方法
CN114215530B (zh) *	2021-11-29	2024-04-19	中国矿业大学	一种坚硬顶板定向水压致裂沿空巷道快速掘巷方法

Also Published As

Publication number	Publication date
US20040005588A1 (en)	2004-01-08
IL154557A0 (en)	2003-09-17
EP1335741A4 (en)	2005-10-26
CA2420499A1 (en)	2002-02-28
WO2002016549A3 (en)	2002-07-18
WO2002016549A2 (en)	2002-02-28
JP2005503320A (ja)	2005-02-03
EP1335741A2 (en)	2003-08-20

Publication	Publication Date	Title
AU2001282475A1 (en)	2002-03-04	Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide
Quintana et al.	2000	Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity
McCluskie et al.	1999	CpG DNA as mucosal adjuvant
US7001890B1 (en)	2006-02-21	Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination
Klinman	2003	CpG DNA as a vaccine adjuvant
JP5123226B2 (ja)	2013-01-23	自己免疫疾患を予防し治療するための物質
Klinman	1998	Therapeutic applications of CpG-containing oligodeoxynucleotides
Jilek et al.	2001	Antigen-independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice
US20190151445A1 (en)	2019-05-23	Combinations of modalities for the treatment of diabetes
MXPA04010415A (es)	2005-02-17	Composiciones oligonucleotdias y su uso para la modulacion de respuestas inmunes.
IL139813A (en)	2007-06-03	Oligonucleotide comprising composition for inducing mucosal immunity
TW201026323A (en)	2010-07-16	Immunostimulatory oligonucleotides
WO2002053106A2 (en)	2002-07-11	Autoantigen composition
WO2014198420A1 (en)	2014-12-18	Low molecular weight immune-modulators as adjuvants for specific immunotherapy
US20040219164A1 (en)	2004-11-04	Advanced antigen presentation platform
CN115768892A (zh)	2023-03-07	包含tlr9激动剂的带状疱疹疫苗
WO2000046365A1 (en)	2000-08-10	Advanced antigen presentation platform
Verthelyi	2006	Adjuvant properties of CpG oligonucleotides in primates
Sakaguchi et al.	2011	Approaches to immunotherapies for Japanese cedar pollinosis
KR100729645B1 (ko)	2007-06-18	글루타민산 데카르복실라제를 코딩하는 유전자가 삽입된재조합 백시니아 바이러스 및 이를 포함하는 제 1형당뇨병 예방 백신
EP1027071A2 (en)	2000-08-16	Encapsulated immunomodulators useful as vaccine adjuvants
AU2005244520B2 (en)	2007-03-08	Substances for preventing and treating autoimmune diseases
AU2003200723B2 (en)	2006-07-27	Encapsulated immunomodulators useful as vaccine adjuvants
US20050096283A1 (en)	2005-05-05	Methods of inhibiting fertility
WO2000025820A1 (en)	2000-05-11	Compounds and methods for genetic immunization

Legal Events

Date	Code	Title	Description
2007-04-26	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application